{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P26651",
      "entity_text" : "TTP",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:387447",
      "entity_text" : "bortezomib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "There is evidence that bortezomib produces a highly statistically significant prolongation of TTP (median 6.22 months) compared to conventional therapy (median 3.49 months) in patients with relapsed multiple myeloma in the APEX trial (XREF_TABLE).",
  "reading_complete" : "2020-08-05T22:29:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:25:20Z",
  "trigger" : "produces",
  "evidence" : [ "bortezomib produces a highly statistically significant prolongation of TTP" ],
  "pmc_id" : "3321668",
  "score" : 0
}